Differentiation Syndrome in Acute Leukemia: APL and Beyond.

Autor: Woods, Ashley C.¹ (AUTHOR) ashley.woods@fda.hhs.gov, Norsworthy, Kelly J.¹ (AUTHOR)

Publikováno v: Cancers. Oct2023, Vol. 15 Issue 19, p4767. 14p.

FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.

Autor: Woods AC; United States Food and Drug Administration, Silver Spring, Maryland, United States., Norsworthy KJ; United States Food and Drug Administration, Silver Spring, MD, United States., Choe M; United States Food and Drug Administration, Silver Spring, Maryland, United States., Gehrke BJ; Food and Drug Administration, White Oak, MD, United States., Chen H; United States Food and Drug Administration, Silver Spring, Maryland, United States., Vallejo J; United States Food and Drug Administration, Silver Spring, MD, United States., Pan L; United States Food and Drug Administration, Silver Spring, Maryland, United States., Jiang X; United States Food and Drug Administration, Silver Spring, Maryland, United States., Li H; United States Food and Drug Administration, Silver Spring, Maryland, United States., Kraft J; United States Food and Drug Administration, United States., Liu J; United States Food and Drug Administration, United States., Charlab R; United States Food and Drug Administration, Silver Spring, MD, United States., Okusanya OO; United States Food and Drug Administration, Silver Spring, MD, United States., Booth B; Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Md, United States., Pazdur R; United States Food and Drug Administration, Silver Spring, MD, United States., Theoret MR; Food and Drug Administration, Silver Spring, MD, United States., de Claro RA; United States Food and Drug Administration, Silver Spring, MD, United States.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Oct 30. Date of Electronic Publication: 2024 Oct 30.